Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Molecular marker and kit for predicting platinum-containing chemotherapy curative effects and lifetime of later-period non-small cell lung cancer

A non-small cell lung cancer, molecular marker technology, applied in the fields of medical molecular genetics and clinical medicine, can solve the problem of different sensitivities of platinum-containing chemotherapy

Inactive Publication Date: 2014-09-03
FUDAN UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, different individuals show significantly different sensitivities to platinum-based chemotherapy in clinical treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1. Molecular markers for predicting the clinical benefit rate and progression-free survival of platinum-containing chemotherapy in patients with advanced non-small cell lung cancer

[0019] 1. Clinical sample collection

[0020] The subjects of the study were 1004 patients with newly diagnosed non-small cell lung cancer. The inclusion criteria were: new history of pathological diagnosis, no previous chemotherapy, surgery and radiotherapy for non-small cell lung cancer; receiving first-line platinum-based chemotherapy; general physical condition score PS 0-2; no major organ dysfunction, blood Routine, liver and kidney functions, and heart functions are basically normal; complete follow-up information can be obtained. All the subjects were unrelated Han people, mainly from Shanghai and its surrounding areas geographically, and all patients were receiving platinum-based first-line treatment for the first time.

[0021] For the above-mentioned included patients,...

Embodiment 2

[0031] Embodiment 2. The use of detection kit

[0032] 1. Genomic DNA extraction

[0033] Genomic DNA was extracted by the saturated sodium chloride method

[0034] 2. Molecular marker typing

[0035] Using the detection kit, first specifically amplify the DNA fragment containing the polymorphic site of RICTOR gene rs6878291, the primer sequence is as follows:

[0036] Forward primer: 5'-CCCATCACTCTTTACCTAAACTCTC-3' (SEQ ID NO.1)

[0037]Reverse primer: 5'-GACTGTGGTAGGCATTTGAAGATA-3' (SEQ ID NO.1)

[0038] The reaction system (20ul) contains: 2μl of 10×Taq buffer, 2μl of 2mM dNTP mixture, 1μl of 1U Taq enzyme, 1μl of sample DNA (about 50ng) and 1μl of 5μM PCR primer. The amplification reaction was carried out on a PCR amplification instrument, and the reaction conditions were: 95°C for 5 minutes; 30 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds; 72°C for 7 minutes; and storage at 4°C.

[0039] The obtained DNA fragments are then sequenced. ...

Embodiment 3

[0046] Example 3. The service of predicting the curative effect of chemotherapy for patients with advanced NSCLC

[0047] 1. Genomic DNA extraction

[0048] The peripheral blood samples of the subjects were collected, and the genomic DNA was extracted by the saturated sodium chloride method.

[0049] 2. Genotyping detection

[0050] Using the kit provided by the present invention, the rs6878291 locus of the RICTOR gene in the genomic DNA of the subject to be tested is typed.

[0051] 3. Predictive analysis of the curative effect of individual platinum-containing chemotherapy

[0052] Through the analysis of the genotype of the rs6878291 site of the tested subject, an evaluation and analysis report of the efficacy of individual platinum-based chemotherapy is issued: if the genotype is A / A or A / G, the clinical benefit rate is 82.1%, and there is no disease progression The median survival time was 9.4 months; if the genotype was G / G, the clinical benefit rate was 69.6%, and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the fields of medical molecular genetics and clinical medicine, and particularly relates to a molecular marker and a kit for predicting the clinical benefit rate and the progression-free survival of platinum-containing chemotherapy for later-period non-small cell lung cancer. The molecular marker comprises an RICTOR gene related to the clinical benefit rate and the progression-free survival of the platinum-containing chemotherapy for the later-period non-small cell lung cancer (NSCLC), and comprises a single-nucleotide polymorphism site rs6878291 on the gene. As an application of the molecular marker, the invention also provides the RICTOR gene polymorphism detection kit for an NSCLC patient prognostic the platinum-containing chemotherapy. The medical molecular and the kit can be used for predicting the clinical benefit rate and the progression-free survival of the platinum-containing chemotherapy for the later-period non-small cell lung cancer, and provides bases for individualized treatment of patients with the disease.

Description

technical field [0001] The invention belongs to the technical fields of medical molecular genetics and clinical medicine, and specifically relates to a molecular marker and a kit for predicting the clinical benefit rate and disease progression-free survival period of advanced non-small cell lung cancer after receiving platinum-containing chemotherapy. Background technique [0002] Malignant tumors are one of the killers that seriously threaten human life and health, and lung cancer is the malignant tumor with the highest morbidity and mortality. The most common type of lung cancer is non-small cell lung cancer (NSCLC), accounting for about About 80% of all lung cancer patients, most of non-small cell lung cancer patients are already in the advanced stage when they are diagnosed, and are no longer suitable for surgical treatment. Therefore, chemotherapy-based comprehensive treatment has become the standard treatment for advanced non-small cell lung cancer. Chemotherapy is wid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6886C12Q2600/106C12Q2600/118C12Q2600/156
Inventor 卢大儒陈红岩王诗铭
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com